

methods for making said products are materially coupled and do not constitute distinct inventions within the meaning proscribed in MPEP § 806.05. Moreover, the close relationship of the subject matter of these groups clearly obviates the need for separate searching and examination by the Office, and coordinate examination of these groups would fulfill the Office's goal of compact prosecution while relieving Applicants of the burden that would attend strict application of the foregoing restriction requirement.

Applicant reserves the right to file a divisional or related application to the claims of non-elected group(s).

AMENDMENT

Please amend the application as follows:

In the Claims

Please cancel claim 95 without prejudice.

Please amend claim 100 as follows:

1 100. (Amended) The isolated infectious PIV particle of
2 claim 91, wherein the [counterpart gene or gene segment is a
3 gene or gene segment of the] recombinant PIV genome or
4 antigenome has one or more HPIV3 HN or F glycoprotein [gene
5 of] genes or gene segments substituted by one or more
6 counterpart HPIV1 or HPIV2 genes or gene segments.

Please add new claims 129-143 as follows:

1 --129. The isolated polynucleotide molecule of
2 claim 4, wherein the HN and F glycoprotein genes of HPIV1
3 are substituted for the counterpart HN and F glycoprotein
4 genes of HPIV3 to encode a chimeric genome or antigenome.

1 130. The isolated polynucleotide molecule of
2 claim 129, wherein the isolated polynucleotide encoding the
3 chimeric PIV genome or antigenome further incorporates one
4 or more mutations of JS cp45.

1 131. The isolated polynucleotide molecule of
2 claim 130, wherein said one or more mutations of JS cp45
3 comprise a plurality and up to a full complement of
4 mutations present in JS cp45.

1 132. The isolated polynucleotide molecule of
2 claim 129, wherein the isolated polynucleotide encoding the
3 chimeric PIV genome or antigenome further incorporates a
4 full complement of mutations present in JS cp45, said full
5 complement of mutations comprising i) substitutions
6 specifying a replacement of His for Tyr₉₄₂, Phe for Leu₉₉₂,
7 and Ile for Thr₁₅₅₈ in the polymerase L protein; ii)
8 substitutions specifying a replacement of Ala for Val₉₆ and
9 Ala for Ser₃₈₉ in the N protein; iii) a substitution
10 specifying a replacement of Thre for Ile₉₆ in the C protein;
11 iv) substitution specifying an amino acid change in the F
12 protein comprising a replacement of Val for Ile₄₂₀ or Thr for
13 Ala₄₅₀; v) substitutions specifying a replacement of Ala for
14 Val₃₈₄ in the HN protein; vi) a substitution specifying a
15 replacement of Thr for Pro₁₉₉ in the M protein; vii)
16 mutations in a 3' leader sequence comprising a T to C change
17 at a position corresponding to nucleotide 23 of JS cp45, a C
18 to T change at nucleotide 24, a G to T change at nucleotide
19 28, and a T to A change at nucleotide 45 of JS cp45; and
20 viii) a mutation in an N gene start sequence comprising an A
21 to T change at a position corresponding to nucleotide 62 of
22 JS cp45.

1 133. The isolated polynucleotide molecule of
2 claim 36, wherein the HN and F glycoprotein genes of HPIV1
3 are substituted for the counterpart HN and F glycoprotein
4 genes of HPIV3.

1 134. The isolated polynucleotide molecule of
2 claim 133, wherein said chimeric genome or antigenome
3 incorporates a full complement of mutations present in JS
4

1 cp45, said full complement of mutations comprising i)
2 substitutions specifying a replacement of His for Tyr₉₄₂, Phe
3 for Leu₉₉₂, and Ile for Thr₁₅₅₈ in the polymerase L protein;
4 ii) substitutions specifying a replacement of Ala for Val₉₆
5 and Ala for Ser₃₈₉ in the N protein; iii) a substitution
6 specifying a replacement of Thre for Ile₉₆ in the C protein;
7 iv) substitution specifying an amino acid change in the F
8 protein comprising a replacement of Val for Ile₄₂₀ or Thr for
9 Ala₄₅₀; v) substitutions specifying a replacement of Ala for
10 Val₃₈₄ in the HN protein; vi) a substitution specifying a
11 replacement of Thr for Pro₁₉₉ in the M protein; vii)
12 mutations in a 3' leader sequence comprising a T to C change
13 at a position corresponding to nucleotide 23 of JS cp45, a C
14 to T change at nucleotide 24, a G to T change at nucleotide
15 28, and a T to A change at nucleotide 45 of JS cp45; and
16 viii) a mutation in an N gene start sequence comprising an A
17 to T change at a position corresponding to nucleotide 62 of
18 JS cp45.

1 135. The method of claim 81, wherein the HN and F
2 glycoprotein genes of HPIV1 are substituted for the
3 counterpart HN and F glycoprotein genes of HPIV3.

1 136. The method of claim 135, wherein said genome
2 or antigenome incorporates a full complement of mutations
3 present in JS cp45, said full complement of mutations
4 comprising i) substitutions specifying a replacement of His
5 for Tyr₉₄₂, Phe for Leu₉₉₂, and Ile for Thr₁₅₅₈ in the
6 polymerase L protein; ii) substitutions specifying a
7 replacement of Ala for Val₉₆ and Ala for Ser₃₈₉ in the N
8 protein; iii) a substitution specifying a replacement of
9 Thre for Ile₉₆ in the C protein; iv) substitution specifying
10 an amino acid change in the F protein comprising a
11 replacement of Val for Ile₄₂₀ or Thr for Ala₄₅₀; v)
12 substitutions specifying a replacement of Ala for Val₃₈₄ in
13 the HN protein; vi) a substitution specifying a replacement

Sub D7
1 of Thr for Pro₁₉₉ in the M protein; vii) mutations in a 3'
2 leader sequence comprising a T to C change at a position
3 corresponding to nucleotide 23 of JS cp45, a C to T change
4 at nucleotide 24, a G to T change at nucleotide 28, and a T
5 to A change at nucleotide 45 of JS cp45; and viii) a
6 mutation in an N gene start sequence comprising an A to T
7 change at a position corresponding to nucleotide 62 of JS
8 cp45.

1 137. The isolated infectious PIV particle of
2 claim 97, wherein HN and F glycoprotein genes of HPIV1 are
3 substituted for counterpart HN and F glycoprotein genes of
4 HPIV3.

1 138. The isolated infectious PIV particle of
2 claim 137, wherein the recombinant PIV genome or antigenome
3 further incorporates one or more mutations of JS cp45.

1 139. The isolated infectious PIV particle of
2 claim 138, wherein said one or more mutations of JS cp45
3 comprise a plurality and up to a full complement of
4 mutations present in JS cp45.

Sub D8
1 140. The isolated infectious PIV particle of
2 claim 137, wherein the isolated polynucleotide encoding the
3 chimeric PIV genome or antigenome further incorporates a
4 full complement of mutations present in JS cp45, said full
5 complement of mutations comprising i) substitutions
6 specifying a replacement of His for Tyr₉₄₂, Phe for Leu₉₉₂,
7 and Ile for Thr₁₅₅₈ in the polymerase L protein; ii)
8 substitutions specifying a replacement of Ala for Val₉₆ and
9 Ala for Ser₃₈₉ in the N protein; iii) a substitution
10 specifying a replacement of Thre for Ile₉₆ in the C protein;
11 iv) substitution specifying an amino acid change in the F
12 protein comprising a replacement of Val for Ile₄₂₀ or Thr for
13 Ala₄₅₀; v) substitutions specifying a replacement of Ala for

1 Val₃₈₄ in the HN protein; vi) a substitution specifying a
2 replacement of Thr for Pro₁₉₉ in the M protein; vii)
3 mutations in a 3' leader sequence comprising a T to C change
4 at a position corresponding to nucleotide 23 of JS cp45, a C
5 to T change at nucleotide 24, a G to T change at nucleotide
6 28, and a T to A change at nucleotide 45 of JS cp45; and
7 viii) a mutation in an N gene start sequence comprising an A
8 to T change at a position corresponding to nucleotide 62 of
9 JS cp45.

1 141. The isolated infectious PIV particle of
2 claim 111, wherein said chimeric PIV genome or antigenome
3 further incorporates the full complement of mutations
4 present in JS cp45, said full complement of mutations
5 comprising i) substitutions specifying a replacement of His
6 for Tyr₉₄₂, Phe for Leu₉₉₂, and Ile for Thr₁₅₅₈ in the
7 polymerase L protein; ii) substitutions specifying a
8 replacement of Ala for Val₉₆ and Ala for Ser₃₈₉ in the N
9 protein; iii) a substitution specifying a replacement of
10 Thre for Ile₉₆ in the C protein; iv) substitution specifying
11 an amino acid change in the F protein comprising a
12 replacement of Val for Ile₄₂₀ or Thr for Ala₄₅₀; v)
13 substitutions specifying a replacement of Ala for Val₃₈₄ in
14 the HN protein; vi) a substitution specifying a replacement
15 of Thr for Pro₁₉₉ in the M protein; vii) mutations in a 3'
16 leader sequence comprising a T to C change at a position
17 corresponding to nucleotide 23 of JS cp45, a C to T change
18 at nucleotide 24, a G to T change at nucleotide 28, and a T
19 to A change at nucleotide 45 of JS cp45; and viii) a
20 mutation in an N gene start sequence comprising an A to T
21 change at a position corresponding to nucleotide 62 of JS
22 cp45.

1 142. The immunogenic composition of claim 124,
2 wherein the HN and F glycoprotein genes of HPIV1 are